Evoke Pharma (EVOK) Q4 2024 earnings summary

Executive summary

• Achieved $10.2 million in total revenue for 2024, a 97% year-over-year increase, with Q4 revenue at $3.3 million, up 24.6% sequentially, surpassing guidance.

• Expanded GIMOTI's prescriber base by 46% year-over-year, reaching 2,553 cumulative prescribers, with fill rates up 72% and patient enrollments up 22%.

• Improved prescription fulfillment and patient access through transition to Aspen/ASPN Pharmacies and expanded distribution network.

• GIMOTI remains the only FDA-approved non-oral treatment for gastroparesis and diabetic gastroparesis, with six Orange Book-listed patents extending into 2030.

• Raised $14.3 million in 2024, extending cash runway into Q1 2026 and ensuring Nasdaq compliance.

Financial highlights

• Net product sales for Q4 2024 were $3.3 million, up from $1.7 million in Q4 2023; full-year 2024 net product sales reached $10.2 million, compared to $5.2 million in 2023.

• Net loss for Q4 2024 was $1.2 million ($0.49/share), improved from $2 million ($7.13/share) in Q4 2023; full-year net loss was $5.4 million ($2.81/share), improved from $7.8 million ($27.97/share) in 2023.

• SG&A expenses for 2024 were $15.1 million, up from $12.2 million in 2023, mainly due to higher marketing and profit-sharing costs.

• Cash and cash equivalents at year-end were $13.6 million.

Outlook and guidance

• Projecting 2025 net revenue of approximately $16 million, a 60% increase over 2024, contingent on current growth rates and external factors.

• Sufficient cash runway into Q1 2026, supported by a $14.3 million capital raise in 2024.

• Plans to expand pharmacy partnerships, increase provider engagement, and leverage real-world data to drive adoption, including hiring field reimbursement managers.